Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: Gurupup who wrote (1237)	3/7/1998 9:49:00 PM
From: vampire	Respond to of 5736

First of all, I don't know what I did to drew you're ire. I just can't stand the way people like David S. were attacked just for disagreeing (though I admit - his disagreements have become personal and uncalled for). In fact, I stand by those comments when I saw how that new person was attacked (I forget his name) for asking questions! After all, if everyone had the time to do exhaustive DD on every stock they got a tip on, then what the hell do we need these boards for??? I thought it was to share info and maybe get others involved. I'm sure the new guy would appreciate the help. Don't forget, if Skip hadn't told all of you about it, you wouldn't be here now either! To the new guy - the reason why everyone on this board is so arrogant is because they KNOW this stock will skyrocket soon - don't let them fool you either with their cut and paste jobs either - they KNOW because Skip told 'em so (and he is right 90% of time) - not because of their DD. Whew - that felt good!

To: Gurupup who wrote (1237)	3/8/1998 10:06:00 AM
From: JanyBlueEyes	Read Replies (4) \| Respond to of 5736

Size of Market Determination Comparison All information regarding Spectrx's numbers was obtained from their prospectus. All information regarding CCSI's numbers was obtained from exchange2000.com - CONFERENCE CALL TRANSCRIPT 9/17/97 Regarding The Size Of The Market =================================== Spectrx: Of the approximately four million newborns each year in the United States, approximately 50% have recognizable jaundice. FYI - From the Merriam Webster Dictionary: recognizable: to perceive clearly perceive: to become aware of through the senses CCSI: The World Health Organization has published the current annual birthrate of approximately 4,000,000 births in the United States, with approximately 10% of these births being premature infants. Spectrx: Annually, approximately 1.7 million newborns receive at least one blood test for bilirubin. Of those newborns tested, approximately 700,000 have elevated bilirubin levels, and a portion of these newborns will receive additional tests. ...The Company believes that the average newborn under active phototherapy treatment receives three to four bilirubin monitoring tests. CCSI: Using numbers of individual bilirubin tests on newborn infants (heelsticks), which are not part of a general panel blood test, the Company estimates there are approximately 15,000,000 bilirubin blood tests currently performed annually, in monitoring Bilirubin infant jaundice in the United States. In making this conservative estimate, the Company assumed averages of one test (not part of a panel test) for full term infants in hospitals before discharge and one test at or after discharge, and an average of 1-2 (or 1.5) tests (not part of a panel test) for premature infants in hospitals during an average length of hospital stay of 11 days, with the remaining tests representing infants treated after discharge. These assumptions were based on publications by the World Health Organization, the American Academy of Pediatrics, independent market studies commissioned by the Company and business proposals from potential marketing partners. Spectrx: The cost to the patient for a bilirubin test ranges from $22.25 to $37.75. CCSI: The Company believes that published amounts for the current reimbursement by third party carriers for heelstick bilirubin tests, not part of a general panel, range between $22-$34 per test in the United States. Assuming a $22 fee, the Company estimates a current annual amount spent on monitoring bilirubin jaundice in the U.S. of $330,000,000. Internationally, using the World Health Organization birthrates, independent market studies and research obtained from companies currently marketing neonatal medical devices in foreign countries, the Company estimates that - the current European market for infant bilirubin tests is approximately the same size as the U.S.- South America, and Canada combined represent approximately 25% of the U.S. market size - and the Southern Chinese and entire Japanese markets combined represent approximately the same size of market as the United States. =================================== Comments: I have found no other data from Spectrx (online) regarding their market studies other than what is shown above. IMO Spectrx is using basic elementary skills when looking at the entire market for bilirubin monitoring. They approach it simply from the actual statistics regarding the condition of jaundice. Bilirubin is monitored for every infant born. CCSI's numbers reflect that perspective, albeit conservatively. So, now you got your point across whether you meant to or not. There is a huge market out there for monitoring bilirubin. Yes, Spectrx will have a share of that market.........CCSI has FDA approval with all the credibility that goes with it.........on almost every page of the Spectrx website regarding their bilicheck you see these haunting words: This product is not available in the U.S. Jane